Chinyorwa ichi chinonyatso ongorora kenza yemakiriniki miedzo muChina mumakore mashoma apfuura, ichitarisa pane zvakakura zvakawanikwa nenzvimbo dzekufambira mberi. Inokurukura zvakare mishonga yegomarara ichangobva kubvumidzwa muChina, ichiongorora maitiro avo, kushanda kubva kumiyedzo, zvinogona kuitika, uye fungidziro yekuwana uye kugona.
Cancer is the biggest cause of death in China, with more than 4.5 million new cases diagnosed each year. Recognizing the seriousness of the condition, the country has made enormous advances in cancer research, transforming it into a hotspot of kliniki miedzo with far-reaching effects. Gone are the days of limited studies targeting a handful of cancers! Today, China has a broad and quickly expanding clinical trial landscape, exploring a wide range of cancers and investigating advanced therapy techniques. 722 clinical trials were made only in the year 2020. The number of cancer clinical trials in China has increased to more than a thousand by the end of 2023.
Miyedzo yekiriniki yeCancer muChina iri kutungamira kubudiriro nyowani mumatanho ekudzivirira, maturusi ekuongorora, mishonga yakanangwa, misanganiswa yeimmunotherapy, uye. CAR T cell kurapwa muChina.
Asi nei zvakakosha kunzwisisa iyi miedzo yekiriniki?
Mhinduro iri mukugona kwavo kurapa varwere vegomarara kwete muChina chete, asi pasirese.
Iyi blog ine chinangwa chekuve gwara rako munyika ino ine simba uye inovimbisa, ichikupa iwe nzwisiso mune ichangoburwa kufambira mberi uye kugona kwavo kuumba ramangwana rekuchengeta cancer.
Gara Uchiziviswa Masero eCAR T Ari Kugadzirisa Ramangwana Rekurapa Gomarara!
Yazvino Mamiriro eCancer Clinical Miedzo muChina
Heano mamwe akakosha ezviyedzo zvekiriniki zvakaitwa mumakore mashoma apfuura -
Immunotherapy iri Kuwedzera
PD-1 inhibitors: Miedzo yakawanda inoongorora PD-1 inhibitors yekenza dzakasiyana siyana, kusanganisira mapapu, chiropa, uye gastric, yakaratidza kushanda nesimba uye kuchengetedza profiles. Zvikuru, tsvagiridzo paPD-1 inhibitor yekenza yemudumbu yakawana kuvandudzwa kwakanyanya mukupona kwepakati kana ichienzaniswa nechemotherapy.
CAR-T cell therapy: Miedzo ye CAR T cell kurapwa kwegomarara muChina, vachipesana neacute lymphoblastic leukemia (ALL) nemamwe magomarara eropa vakaratidza kuregererwa kwakakwana kwemazinga, vachiwedzera tariro yemhinduro dzekurapa dzemunhu. Mazhinji masangano anoremekedzwa ehutano muChina ari kupa kurapwa kenza pasina muChina sechikamu chekuedzwa kwekiriniki kune avo vasingakwanise kubhadhara mari yekurapa cancer.
Kufambira mberi muPrecision Medicine
Targeted therapeutics: Trials of targeted therapies aiming to exploit specific genetic alterations in tumors are showing promising outcomes. For example, research using a tyrosine kinase inhibitor specific to a KRAS mutation in lung cancer resulted in considerable tumarara reduction and prolonged progression-free survival.
Liquid biopsy: Nzira dzisiri-invasive liquid biopsy yakavakirwa pakutenderera bundu DNA (ctDNA) iri kuwedzera kushandiswa kuronda mhinduro yekurapa uye kuona masaini ekutanga ekudzokazve. Zvidzidzo zvekutanga zvinoongorora kugona kwavo kwekugadzirisa kurapwa kwemunhu zviri kuenderera mberi.
Kusiyana neyakajairwa invasive tishu biopsies, mvura biopsies inoziva uye inoratidza gomarara vachishandisa biomarker iri mumagetsi emuviri, seropa. Liquid biopsies, iyo inoda chete sampuli yeropa, inogonesa yakachengeteka uye inodzokororwa kuyedzwa, ichibvumira chaiyo-nguva yekutarisa kufambira mberi kwechirwere uye mhinduro yekurapa.
Traditional Medicine Integration
Combining traditional Chinese medicine (TCM) with Western therapies: Several studies are looking into the synergistic effects of TCM herbs and traditional techniques for reducing cancer side effects and boosting treatment success. Examples include studies that combined TCM with chemotherapy for lung cancer and radiation therapy for nasopharyngeal carcinoma.
Ziva Hope : Sei PET CT Scan iri Kuchinja Hupenyu hweVarwere veCancer Munyika Yose?
China's Medical Administration Yakabvumidza Mushonga Mutsva WeMetastatic Biliary Tract Cancer
Good news for patients with metastatic biliary tract cancer (BTC)! The National Medical Products Administration (NMPA) of China has approved Imfinzi (durvalumab), an immunotherapy medication, in combination with conventional chemotherapy for first-line treatment.
Ichi chiitiko chikuru, sezvo chinopa sarudzo nyowani, inoshanda kune varwere ava, vanowanzova nehutsinye hwekufungidzira.
Sei Rudzi urwu rwemushonga rwakakosha muCancer Care?
Biliary tract cancer igomarara rine hasha rine sarudzo shoma dzekurapa. Kukurumidza kuongororwa hakuna kujairika, uye mwero wekupona wakaderera.
Imfinzi, pamwe chete nechemotherapy, yakaunza zvibereko zvakanaka. Mumakiriniki ekuedzwa, varwere vakagamuchira musanganiswa uyu vaive ne22% yakaderera njodzi yerufu pane avo vakangogamuchira chemotherapy. Izvi zvakaguma nekugara kwenguva refu uye hupenyu hunogona kuve huri nani.
Imfinzi yakatotenderwa kune dzimwe nyika, uye mvumo iyi inoita kuti kurapwa kuvepo kune varwere muChina, uko kunoda kusvika 20% yezviitiko zveBTC zvepasi rose zvinoitika.
Imfinzi Inoshanda Sei?
Ndecheboka remishonga yegomarara inodaidzwa kuti immunotherapy, iyo inoshandisa immune system yemuviri kurwisa cancer. Imfinzi inonangwa uye inhibits PD-L1, puroteni inoshandiswa nemasero egomarara kudzivirira immune system. Izvi zvinovandudza kugona kwemasero edziviriro kuziva uye kurwisa tumor cell.
Kunyange zvazvo idzi dziri nhau dzakanaka, tsvakurudzo yakawanda inodiwa munzvimbo iyi. Mamiriro enguva refu uye kubudirira muhuwandu hwevarwere vakasiyana zvinoda kudzidzwa.
Zvakadaro, kubvumidzwa uku kunounza tariro nyowani kune biliary turakiti cancer varwere uye inosimbisa kugona kwe immunotherapy mukurapa cancer.
Wedzera Kuziva Kwako: Kunyatsotarisa Pamatanho Akasiyana Eakawanda Myeloma
Kenza Yekiriniki Miedzo muChina Yakatungamira Kukudziridzwa Kwekuvandudza Marapirwo
Kuzvipira kweChina kutsvagurudzo yegomarara kuri kuburitsa mhedzisiro yakanaka, nemiedzo yekiriniki ichiita basa rakakosha mukuvandudza nzira dzekurapa dzegomarara.
CAR-T Cell Therapy
CAR-T cell therapy inzira inovimbisa uye inoshandura cancer yekurapa iyo ichangobva kuita budiriro yakakosha muzvidzidzo zvekiriniki muChina. CAR-T cell kurapa zvinosanganisira kushandura masero eT emurwere kuti ataure chimeric antigen receptors (CARs), ayo anoziva nekuparadza masero emamota.
Multiple trials in China over the last few years have perfected CAR-T manufacture and delivery systems, resulting in impressive response rates in certain refractory blood cancers like lymphoma and leukemia when other therapies have failed.
Imwe nzvimbo yekutsvagisa inoenderera mberi ndeyekuvandudzwa kwe CAR-T mishonga kunanga maantigen matsva akabatana nehupamhi hwakawanda hwehematologic uye akasimba bundu.
PD-1 Inhibitors
PD-1 inhibitors yakaita kufambira mberi kwakanyanya mugomarara immunotherapy. Mumakore achangopfuura, miedzo yakawanda yekiriniki muChina yakaongorora PD-1 inhibitor masoja ekudzivirira chirwere achipesana nemhando dzakasiyana dzegomarara.
Mishonga iyi inoita sezvivhariso zvidiki, kudzivirira maseru egomarara kutumira "masaini ekumisa" kumaseru ekudzivirira T. Nezvipingamupinyi izvi munzvimbo, T masero anosunungurwa, kuziva uye kurwisa kenza nekuwedzera simba.
Notably, PD-1 inhibitors have shown great promise in isina-diki kenza yemapapu kenza trials, boosting overall response rates, progression-free survival, and overall survival when compared to chemotherapy.
Targeted Therapies
Targeted cancer therapy that specifically inhibits specific genetic drivers of tumor development and progression has emerged as a key pillar of precision oncology. The most rapid advancement in targeted therapy has happened in kenza yemapapu, with recent China trials of agents like anlotinib, and icotinib finding promising response rates and survival improvements, leading to several regulatory approvals. Trials are also examining targeted therapies matched to biomarkers in liver, gastric, and kenza dzakajeka.
Combination Therapies
Mishonga yemasanganiswa, iyo inoshandisa mishonga miviri kana kupfuura ine nzira dzakasiyana, iri kuwedzera mukurumbira mukurwisa gomarara kweChina. Iyi nzira ine chinangwa chekugadzirisa miganhu ye-single-agent therapy nekugona kuwedzera kushanda, kuderedza kuramba, uye kuderedza migumisiro yakaipa.
Iko kusanganiswa kweanonangwa kurapa ne immunotherapy, gene therapy, kana mamwe marapirwo ari kuongororwa zvakanyanya kuti awane synergistic mabhenefiti achipokana nemhando dzakasiyana dzegomarara.
Misanganiswa iyi iri kuratidza kuwirirana kwakasiyana, nemiyedzo ichangoburwa inoratidza mhinduro dzinosvika makumi mapfumbamwe muzana pasina humwe huturu kana zvichienzaniswa nemishonga imwe chete.
Tumor-Infiltrating Lymphocyte Therapy
Tumor Infiltrating Lymphocytes (TIL) kurapwa inzira ine simba uye yakasarudzika yekuzvidzivirira kune mamwe mamota akasimba. Inomisikidza immune system yemurwere nekuunganidza uye nekuwanza tumor-kurwisa T masero anogara aripo mukati mebundu. Aya "masoja akadzidziswa," anozivikanwa seTILs, anobva adzoserwa mumurwere, akagadzirira kuziva uye kubvisa masero egomarara.
Kusiyana neCAR T masero, anogadzirwa kuti atarise chaiwo mamaki pamasero egomarara, TILs vane pundutso huru: vanocherechedza mhatsa yakawanda yezvinangwa pabundu remurwere. Izvi zvinodaro nekuti ivo vakatopinda mubundu microenvironment, vachidzidza "zvigunwe" zvemuvengi.
Iyi nzira ine-multi-pronged inoita kuti zvinyanye kuomera bundu kunzvenga kurapwa nekuviga chinangwa chimwe chete, chinopa rubatsiro rwakakura rwekurapa.
Cancer Clinical Miedzo muChina Iri Kuwana Kutariswa Kwepasirese
Kuzvipira kweChina kutsvagiridzo yegomarara kuri kuburitsa mhedzisiro yakanaka, nemiedzo yekiriniki ichiita basa rakakosha mukuvandudza marapirwo matsva. Kuwedzera kwekuita uku hakungomiriri kufambira mberi kukuru kweChina chete asi kunopawo tariro yehondo yepasi rose yekurwisa cancer.
Kukura Kwenhamba Uye Kusiyana
Huwandu hwemiyedzo yekiriniki muChina huri kuwedzera, huchivhara huwandu hwakasiyana hwegomarara, kubva kune akajairwa mafomu akadai sekenza yemapapu uye yemudumbu kusvika kune asina kujairika. Izvi zvakasiyana-siyana zvinoita kuti vatsvakurudzi vaongorore zvakasiyana-siyana marapirwo egomarara.
Advanced Therapies
Vatsvagiri vari kuongorora ma immunotherapies matsva akadai seCAR-T cell therapy uye PD-1 inhibitors, pamwe nekurapa kwemajini nemishonga yakanangwa zvichienderana nekuchinja kwemajini. Izvi zvine vimbiso yekurapa kwemunhu uye zvirongwa zvekurapa zvinoshanda.
Liquid Biopsy Revolution
China iri kushingairira kudzidza liquid biopsy, isinga pindike nzira yekuongorora ropa rebundu reDNA nezvimwe zviratidzo. Izvi zvinovhura mikova yekukurumidza kuonekwa uye chaiyo-nguva yekutarisa mhinduro dzekurapa.
Kudyidzana Uye Innovation
China iri kuramba ichishanda nevatsvagiri vepasirese nemasangano kufambisa shanduko yeruzivo uye kukurumidzira kuvandudzwa kwekurapa kwehunyanzvi. Izvi zvinokurudzira nzira yepasi rose yekutsvaga cancer, iyo inobatsira varwere pasi rose.
Final Thoughts
Sezvatinopedzisa chinyorwa ichi chegomarara kuyedzwa kwekiriniki muChina, zvakakosha kuti uzive kuti uku ndiko kutanga. Iyi miyedzo irikuenderera mberi, inotangira pakuchinja immunotherapies kuenda kune yakasarudzika nzira dzekurapa, ine zvinobata zvinosvika kure kumiganhu yenyika. Nhanho imwe neimwe yekuenda mberi muChina ine simba repasi rose, ichipa tariro kune vanorwara nekuvandudza kurwisa chirwere ichi chakaoma.
